Page last updated: 2024-10-19

phosphorylcholine and Skin Diseases

phosphorylcholine has been researched along with Skin Diseases in 2 studies

Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.

Skin Diseases: Diseases involving the DERMIS or EPIDERMIS.

Research Excerpts

ExcerptRelevanceReference
"Miltefosine has been approved for oral and topical treatment of leishmaniasis and may also be a promising candidate for the topical treatment of Acanthamoeba infections."1.35Anti-acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent. ( Auer, H; DuchĂȘne, M; Gruber, F; Mildner, M; Obwaller, A; Suchomel, M; Tschachler, E; Walochnik, J, 2009)
"In patients with breast cancer and skin metastases, topically applied miltefosine solution yields at least partial regression of the lesions in approximately a quarter of patients when used as an adjunct to standard treatment (surgery, radiotherapy, systemic chemotherapy or hormone therapy) or when standard treatments are contraindicated."1.30Miltefosine: new preparation. Solution for cutaneous application. ( , 1998)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Walochnik, J1
Obwaller, A1
Gruber, F1
Mildner, M1
Tschachler, E1
Suchomel, M1
DuchĂȘne, M1
Auer, H1

Other Studies

2 other studies available for phosphorylcholine and Skin Diseases

ArticleYear
Anti-acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:3

    Topics: Acanthamoeba; Animals; Antiprotozoal Agents; Candida albicans; Drug Stability; Drug Storage; Humans;

2009
Miltefosine: new preparation. Solution for cutaneous application.
    Prescrire international, 1998, Volume: 7, Issue:33

    Topics: Administration, Cutaneous; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Clinical Trial

1998